ADVISORY, July 16, 2014 (GLOBE NEWSWIRE) --
Dipexium Pharmaceuticals, Inc. (Nasdaq:DPRX), a late stage pharmaceutical company developing Locilex™ (pexiganan acetate cream 1%), a proposed antibiotic treatment for mild infections of diabetic foot ulcers, will visit the NASDAQ MarketSite in Times Square.
In honor of the occasion, Messrs. David P. Luci, President & CEO and Robert J. DeLuccia, Executive Chairman will ring the Closing Bell.
NASDAQ MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio
Thursday, July 17, 2014 – 3:45 p.m. to 4:00 p.m. ET
Dipexium Pharmaceuticals, Inc. Contact:
Fiber Line (Encompass Waterfront): 4463
Gal 3C/06C 95.05 degrees West
18 mhz Lower
DL 3811 Vertical
For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies please visit our Facebook page at: http://www.facebook.com/NASDAQ.
For photos from ceremonies and events visit our Instagram Page: http://instagram.com/nasdaq.
For news tweets, please visit our Twitter page at: http://twitter.com/nasdaqomx.
For exciting viral content and ceremony photos visit Tumblr Page: http://nasdaq.tumblr.com/.
A webcast of the NASDAQ Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About Dipexium Pharmaceuticals, Inc. (Nasdaq:DPRX):
Dipexium Pharmaceuticals, Inc. (Nasdaq:DPRX) is a late-stage pharmaceutical company focused on the development and commercialization of Locilex® (pexiganan cream 0.8%), a novel, broad-spectrum, topical antibiotic peptide. Initially, Locilex® is targeted for the treatment of mild infections of diabetic foot ulcers. Based on a compilation of available clinical and microbiology data, Locilex® is also considered a promising product candidate to treat other mild and moderate bacterial skin infections in superficial wounds, including infected decubitus ulcers, infected burns, infected surgical wounds and nasal colonization of methicillin-resistant staphylococcus aureus (MRSA). For additional information about the company, please visit www.dipexiumpharmaceuticals.com.
About NASDAQ OMX Group
NASDAQ OMX (Nasdaq:NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents. Through its diverse portfolio of solutions, NASDAQ OMX enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. NASDAQ OMX is home to more than 3,400 listed companies with a market value of over $8.5 trillion and more than 10,000 corporate clients. To learn more, visit www.nasdaqomx.com.